103 related articles for article (PubMed ID: 1360872)
1. In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fc gamma receptor III.
Hsieh-Ma ST; Eaton AM; Shi T; Ring DB
Cancer Res; 1992 Dec; 52(24):6832-9. PubMed ID: 1360872
[TBL] [Abstract][Full Text] [Related]
2. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
3. Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1.
Weiner LM; Holmes M; Richeson A; Godwin A; Adams GP; Hsieh-Ma ST; Ring DB; Alpaugh RK
J Immunol; 1993 Sep; 151(5):2877-86. PubMed ID: 8103070
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
Weiner LM; Clark JI; Davey M; Li WS; Garcia de Palazzo I; Ring DB; Alpaugh RK
Cancer Res; 1995 Oct; 55(20):4586-93. PubMed ID: 7553634
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM
Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012
[TBL] [Abstract][Full Text] [Related]
6. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
[TBL] [Abstract][Full Text] [Related]
7. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
Weiner LM; Clark JI; Ring DB; Alpaugh RK
J Hematother; 1995 Oct; 4(5):453-6. PubMed ID: 8581384
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.
Garcia de Palazzo I; Holmes M; Gercel-Taylor C; Weiner LM
Cancer Res; 1992 Oct; 52(20):5713-9. PubMed ID: 1394194
[TBL] [Abstract][Full Text] [Related]
9. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
[TBL] [Abstract][Full Text] [Related]
10. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
[TBL] [Abstract][Full Text] [Related]
11. Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fc gamma RIII.
Weiner LM; Alpaugh RK; Amoroso AR; Adams GP; Ring DB; Barth MW
Cancer Immunol Immunother; 1996 Mar; 42(3):141-50. PubMed ID: 8640842
[TBL] [Abstract][Full Text] [Related]
12. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing.
Coney LR; Mezzanzanica D; Sanborn D; Casalini P; Colnaghi MI; Zurawski VR
Cancer Res; 1994 May; 54(9):2448-55. PubMed ID: 7512887
[TBL] [Abstract][Full Text] [Related]
13. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.
Heijnen IA; Rijks LJ; Schiel A; Stockmeyer B; van Ojik HH; Dechant M; Valerius T; Keler T; Tutt AL; Glennie MJ; van Royen EA; Capel PJ; van de Winkel JG
J Immunol; 1997 Dec; 159(11):5629-39. PubMed ID: 9548506
[TBL] [Abstract][Full Text] [Related]
14. Fc gamma RI and Fc gamma RII on monocytes and granulocytes are cytotoxic trigger molecules for tumor cells.
Graziano RF; Fanger MW
J Immunol; 1987 Nov; 139(10):3536-41. PubMed ID: 2960735
[TBL] [Abstract][Full Text] [Related]
15. Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells.
Somasundaram C; Sundarapandiyan K; Keler T; Deo YM; Graziano RF
Hum Antibodies; 1999; 9(1):47-54. PubMed ID: 10331185
[TBL] [Abstract][Full Text] [Related]
16. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment.
Clark JI; Alpaugh RK; von Mehren M; Schultz J; Gralow JR; Cheever MA; Ring DB; Weiner LM
Cancer Immunol Immunother; 1997 Jul; 44(5):265-72. PubMed ID: 9247561
[TBL] [Abstract][Full Text] [Related]
17. Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.
Deo YM; Sundarapandiyan K; Keler T; Wallace PK; Graziano RF
J Immunol; 1998 Feb; 160(4):1677-86. PubMed ID: 9469424
[TBL] [Abstract][Full Text] [Related]
18. Functions of the various IgG Fc receptors in mediating killing of Toxoplasma gondii.
Erbe DV; Pfefferkorn ER; Fanger MW
J Immunol; 1991 May; 146(9):3145-51. PubMed ID: 1826707
[TBL] [Abstract][Full Text] [Related]
19. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
[TBL] [Abstract][Full Text] [Related]
20. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion.
Johnson S; Burke S; Huang L; Gorlatov S; Li H; Wang W; Zhang W; Tuaillon N; Rainey J; Barat B; Yang Y; Jin L; Ciccarone V; Moore PA; Koenig S; Bonvini E
J Mol Biol; 2010 Jun; 399(3):436-49. PubMed ID: 20382161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
